Key result
Novel therapeutic targets for WHO Group I pulmonary arterial hypertension are currently under investigation, requiring large clinical trials to validate their safety and efficacy.
Why the study?
Despite increased therapeutic options targeting three major pathophysiological mechanisms, prognosis remains unsatisfactory for many patients with PAH, prompting investigation into novel therapeutic targets.
This review highlights emerging therapeutic targets and novel pathophysiological pathways for the treatment of WHO Group I pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Current evidence insufficient to guide PAH therapy; leaves open validation of novel targets in definitive trials.
Since the discovery of three major pathophysiological mechanisms of pulmonary arterial hypertension (PAH), including prostacyclin, endothelin and nitric oxide pathways, the therapeutic options for PAH have increased. Nevertheless, despite these advances, the prognosis remains unsatisfactory for many patients with PAH. With the progress of both pre-clinical and clinical research on PAH, several novel therapeutic targets have been identified for the treatment of PAH. In this study, we review updated information of novel pathophysiological pathways of pulmonary hypertension, mainly focusing on WHO Group I PAH. Drugs based on these pathways are currently under clinical or pre-clinical investigation, however they have been approved for clinical use. Large clinical trials are required to validate the clinical safety and effects of these novel therapies.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2022) conducted a review in Pulmonary arterial hypertension (WHO Group I PAH). Novel therapeutic targets and drugs was evaluated. Novel therapeutic targets for WHO Group I pulmonary arterial hypertension are currently under investigation, requiring large clinical trials to validate their safety and efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: